Previously, loss-of-function mutations in BRCA1 and FBXW7, an E3 ubiquitin ligase that marks cyclin E for proteolytic destruction [15], were associated with clinical benefit in patients with HNSCC or SCCA [12]. The gene discussed is BRCA1; the disease is head and neck squamous cell carcinoma.